Category: Diabetes

Introduction and Objective: Bedside clinical methods to screen diabetic peripheral neuropathy (DPN) are not reproducible and detect DPN late. In a recent study of diabetes patients, DPN was detected in 14.4% using the 10 g monofilament (10gMF), increasing to 51.5% with DPN-Check, a point-of-care device measuring sural nerve conduction velocity and amplitude. We evaluated whether […]

Introduction and Objective: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) prescription increased rapidly in Medicare for type 2 diabetes (T2D), with limited evidence on medical expenditures. We estimated expenditure changes using a matched controlled design.Methods: Using 2015-2023 Medicare fee-for-service claims, we identified beneficiaries aged ≥67 years with prevalent T2D, continuous Part A, B, and D enrollment, […]

Introduction and Objective: Rural populations experience higher diabetes burden and barriers to care. RDMPs may mitigate geographic barriers; however, evidence comparing rural and urban populations remains limited. The objective of this study was to evaluate whether enrollment (ENR), engagement (ENG), and glycemic outcomes among rural participants in an RDMP were non-inferior to urban participants.Methods: We […]

Introduction and Objective: The health and psychosocial impacts of recurrent severe hypoglycemic events (SHEs) and impaired awareness of hypoglycemia (IAH) in adults with type 1 diabetes (T1D) who use continuous glucose monitors (CGM) and insulin pumps remain poorly understood. This study describes the health and psychosocial burden of adults with T1D using CGM and insulin […]

Introduction and Objective: Insulin pump-based Automated Insulin Delivery (AID) therapy has significantly improved glucose control and reduced hypoglycemic risk in patients with Type 1 Diabetes (T1D), but is currently only approved to use with U-100 insulin, which can be problematic in patients with severe insulin resistance, due to frequent cartridge volume exhaustion, infusion site saturation, […]

Introduction and Objective: Although worsening glycemic control during the menstrual cycle (MC) has been reported in type 1 diabetes (T1D), the influence of premenstrual syndrome (PMS) remains poorly defined. Objectives: i) To characterize PMS severity across MC phases; ii) To evaluate associations between PMS severity and glycemic control, (iii) To assess whether higher PMS severity […]

Introduction and Objective: This post hoc analysis assessed efficacy and hypoglycemia outcomes of IcoSema (a once-weekly combination of insulin icodec + semaglutide) vs comparators (COMBINE 1 [C1]: icodec; COMBINE 2 [C2]: semaglutide 1.0 mg; COMBINE 3 [C3]: basal-bolus therapy) in insulin-experienced (C1+3) or GLP-1 RA experienced (C2) adults with T2D by baseline BMI subgroups.Methods: Treatment […]

Introduction and Objective: Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated superior glycemic and weight-loss efficacy in randomized trials. However, real-world evidence in South Asian populations remains limited. This study was done to evaluate the early real-world effectiveness and safety of tirzepatide in Indian adults with type 2 […]

Introduction and Objective: Type 1 diabetes (T1D) is an autoimmune disorder marked by islet autoantibodies. First-degree relatives (FDRs) of individuals with T1D have a 10-15-fold higher risk of developing T1D than the general population. Screening for four autoantibodies—glutamic acid decarboxylase (anti-GAD), protein tyrosine phosphatase (anti-IA2), insulin (IAA), and Zinc Transporter 8 (anti-ZnT8)—enables early detection of […]

Introduction and Objective: The literature reports that Mexican American children are at risk for diabetes, hypertension, renal dysfunction, cardiovascular and gallbladder disease, risk increases if the child has overweight or obesity. In 2005 we found that by the age of three 25% of boys and 15% of girls were either overweight or obese, but the […]